Skip to main content
Premium Trial:

Request an Annual Quote

Santaris, Pfizer Expand LNA Drug Collaboration

Premium

Santaris Pharma said this week that its worldwide strategic alliance with Pfizer has been expanded, triggering a $14 million payment from the big pharma for access to Santaris' locked nucleic acid technology for the development of RNA-targeting drugs.

The deal was first struck in 2009 between Santaris and Wyeth (GSN 1/15/2009). Under the terms of the deal, Wyeth was to select up to 10 targets against which Santaris would create LNA-based drug candidates, although a Wyeth official told Gene Silencing News at the time that the company had no plans to pursue microRNA targets.

Pfizer inherited the partnership when it acquired Wyeth late in 2009.

Under the terms of the expanded arrangement, Santaris stands to receive up to $600 million in milestones, plus royalties, on products developed through the collaboration.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.